No connection

Search Results

GILD vs TMO

GILD
Gilead Sciences, Inc.
NEUTRAL
Price
$132.90
Market Cap
$164.96B
Sector
Healthcare
AI Confidence
85%
TMO
Thermo Fisher Scientific Inc.
NEUTRAL
Price
$513.98
Market Cap
$191.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GILD
19.6
TMO
28.99
Forward P/E
GILD
13.81
TMO
18.94
P/B Ratio
GILD
7.27
TMO
3.62
P/S Ratio
GILD
5.6
TMO
4.29
EV/EBITDA
GILD
12.4
TMO
19.96

Profitability

Gross Margin
GILD
78.84%
TMO
41.08%
Operating Margin
GILD
37.38%
TMO
21.17%
Profit Margin
GILD
28.9%
TMO
15.05%
ROE
GILD
40.66%
TMO
13.02%
ROA
GILD
12.52%
TMO
5.03%

Growth

Revenue Growth
GILD
4.7%
TMO
7.2%
Earnings Growth
GILD
23.4%
TMO
9.3%

Financial Health

Debt/Equity
GILD
1.13
TMO
0.77
Current Ratio
GILD
1.55
TMO
1.89
Quick Ratio
GILD
1.23
TMO
1.36

Dividends

Dividend Yield
GILD
2.47%
TMO
0.34%
Payout Ratio
GILD
46.61%
TMO
9.7%

AI Verdict

GILD NEUTRAL

GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.

Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth
TMO NEUTRAL

TMO exhibits exceptional operational health with a Piotroski F-Score of 8/9, indicating strong financial stability and efficiency. However, the stock is currently trading at a significant premium, with a current price of $513.98 far exceeding both the Graham Number ($237.97) and the growth-based Intrinsic Value ($371.44). While analyst sentiment remains strongly bullish with a target of $647.38, this is countered by bearish insider activity and a negative technical trend. The outlook is balanced between high-quality fundamentals and a stretched valuation.

Strengths
Strong financial health evidenced by a Piotroski F-Score of 8/9
Consistent track record of earnings beats over 25 quarters
Healthy liquidity with a current ratio of 1.89 and quick ratio of 1.36
Risks
Significant valuation gap between current price and deterministic fair value models
Bearish insider sentiment with over $56M in sales by the CEO and COO
Negative technical trend (0/100) indicating short-term price weakness

Compare Another Pair

GILD vs TMO: Head-to-Head Comparison

This page compares Gilead Sciences, Inc. (GILD) and Thermo Fisher Scientific Inc. (TMO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile